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Abstract: 
The US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders 
and Genetic Diseases in Newborns and Children provides guidance to reduce the morbidity and 
mortality associated with heritable disorders, with a special emphasis on those conditions 
detectable through newborn screening. Although long-term follow-up is necessary to maximize 
the benefit of diagnosis through newborn screening, such care is variable and inconsistent. To 
begin to improve long-term follow-up, the Advisory Committee has identified its key features, 
including the assurance and provision of quality chronic disease management, condition-specific 
treatment, and age-appropriate preventive care throughout the lifespan of affected individuals. 
There are four components central to achieving long-term follow-up: care coordination through a 
medical home, evidence-based treatment, continuous quality improvement, and new knowledge 
discovery. 
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Article: 
Newborn screening is an essential public health function provided to all newborns in the United 
States. The newborn screening system is intended to be comprehensive, including not only 
screening and diagnosis, but also long-term follow-up care through the medical home.1 All of 
the conditions identifiable through newborn screening are chronic, and therefore require medical 
care and other related services throughout the affected individual's lifetime. Unfortunately, the 
long-term follow-up activities within public health programs lack coordination and have been of 
low priority for funding compared with activities related to screening and diagnosis.2,3 
 
In the treatment and management of a condition, affected individuals and their families may 
regularly interact with generalist physicians, specialist physicians, primary care and specialty 
nurses, clinical psychologists, dentists, nutritionists, genetic counselors, occupational and 
physical therapists, education specialists, public health nurses, social workers, and pharmacists. 
These interactions are complex because most conditions identified through newborn screening 
have a wide variety of manifestations and related comorbidities, the treatment evidence-base is 
not always definitive, effective models of comanagement are not in place, and there is a 
maldistribution and lack of accessibility of knowledgeable care providers. Further complicating 
long-term follow-up, affected individuals, families, and care providers must interact with both 
private and public payers, and insurance health benefits are variable and often incomplete. 
 
To begin to improve the long-term follow-up component of the newborn screening system, this 
statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable 
Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC; roster of members 
available at http://www.hrsa.gov/heritabledisorderscommittee/governance/roster.htm) defines the 
key features of long-term follow-up. The statement was developed from the comments of an 
expert panel of health care policy experts, public health specialists, generalist and specialist care 
providers, allied health care providers, and the families of affected individuals convened in April 
2007, and approved by the ACHDGDNC. It greatly expands the concept of long-term follow-up 
from data management to systematic and comprehensive care of affected individuals. The 
statement does not address how these components will be implemented or supported; those 
discussions are ongoing. 
 
GOAL OF LONG-TERM FOLLOW-UP 
The principal goal of long-term term follow-up is to assure the best possible outcome for 
individuals with disorders identified through newborn screening. The time frame for long-term 
follow-up is the lifespan of the affected individual; however, the responsibility of the 
ACHDGDNC as set by its authorizing legislation is from birth to age 21 years. 
 
DEFINITION OF LONG-TERM FOLLOW-UP 
Fundamentally, long-term follow-up comprises the assurance and provision of quality chronic 
disease management, condition-specific treatment, and age-appropriate preventive care 
throughout the lifespan of individuals identified with a condition included in newborn screening. 
Integral to assuring appropriate long-term follow-up are activities related to improving care 
delivery, including engagement of affected individuals and their families as effective partners in 
care management, continuous quality improvement through the medical home, research into 
pathophysiology and treatment options, and active surveillance and evaluation of data related to 
care and outcomes. 
 
COMPONENTS OF LONG-TERM FOLLOW-UP CARE 
Care coordination through a medical home 
The ACHDGDNC supports the concept that all individuals diagnosed with a condition through 
newborn screening should have a medical home to integrate care and ensure quality and safety in 
care delivery.4,5 As the usual place for sick and well care, the medical home should be family-
centered, culturally effective, accessible, actively engaged in the coordination and provision of 
primary and subspecialty health care services within the health care system and across other 
community-based agencies and services (e.g., other clinicians, educational programs, and 
community-based counseling and support services),4,5 and facilitate requisite referrals. Systems 
will need to be developed to assure that individuals transition to adult care services without 
losing a medical home; this is central to the receipt of long-term follow-up care.2,6 
Evidence-based treatment 
Provision of condition-specific therapy is a critical component of long-term follow-up care. For 
many of the conditions identified by newborn screening, specific and often expensive therapeutic 
agents, including specialized nutritional formulas, are required over the life of the affected 
individual. For some of the conditions, the most effective treatment is uncertain. The current 
evidence base for these conditions is limited because their rarity and heterogeneity makes 
randomized controlled trials and even prospective observational cohort studies difficult to carry 
out.7 More emphasis needs to be placed on collating and distributing “best practices” based on 
existing evidence, even for those conditions with evolving treatment protocols. This process will 
be central to the development of clinical care guidelines. A critical component of long-term 
follow-up care is a coordinated mechanism for both collecting and synthesizing information 
about effective treatments and connecting affected individuals with the most effective treatments 
or clinical research trials if the appropriate management is uncertain. 
Continuous quality improvement 
Long-term follow-up data systems should allow clinicians, experts in quality improvement, 
researchers, affected individuals and their families, public health officials, and policy makers to 
evaluate the care that affected individuals and their families actually receive. These activities 
should focus on three separate areas: adherence to clinical guidelines or accepted best practice, 
evaluation of the effectiveness of various treatment/intervention protocols, and assessments of 
the experience with care of affected individuals and their families. These data could be analyzed 
to identify problems in quality of care across conditions and care settings that could be remedied 
with more broad-based actions such as technical assistance for quality improvement. Long-term 
follow-up information systems that capture appropriate clinical and other relevant care 
information will be required to assure quality improvement. Integrating such care information 
with public health data and the analysis of the information will provide knowledge to support 
informed decision-making that addresses clinical, public health, and health policy needs. 
New knowledge discovery 
Long-term follow-up information systems should provide a platform for basic science and 
clinical researchers to assess genotype-phenotype relationships, including the natural history of 
conditions, and to engage individuals and families as partners in research to evaluate the impact 
of interventions, including novel therapies and those current therapies that lack high-quality 
evidence of effectiveness. Such registry-based approaches to discovery are needed to overcome 
the challenges of research in rare conditions and fill in critical gaps in the evidence base. If we 
are to understand the many, often rare conditions detected by newborn screening, it will be 
important not only to track clinical and laboratory information as children grow, but also to 
provide their treatment within a research context that is family-centered and culturally 
competent. To be most efficient, the system developed for quality improvement should also be 
able to collect data regarding treatment effectiveness. 
NEXT STEPS 
This statement defines the major components of newborn screening long-term follow-up. 
Although this document addresses the long-term follow-up needs of children identified through 
the newborn screening system, it is acknowledged that some children will not be included from 
the outset because of limitations in the screening and short-term follow-up system (e.g., false-
negatives) or to unique characteristics of the condition (e.g., late-onset hearing loss) The 
framework of long-term follow-up, however, applies for all children with a specific condition 
included in the NBS panel, regardless of how that child's condition is ultimately identified. The 
ACHDGDNC understands that there are many barriers to implementing long-term follow-up. 
These barriers are not only related to cost of implementation, but to other health care system 
factors (e.g., lack of public health infrastructure, maldistribution of providers, inefficient models 
of comanagement, variations in the availability and use of health information technology, lack of 
electronic health record interoperability) and to potential consequences for affected individuals 
and their families (e.g., loss of privacy and other human subject protection concerns and risks to 
insurability). The ACHDGDNC will next develop a roadmap for implementation. 
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